About vedolizumab
Gut-selective integrin receptor antagonist
Used for
- Treats moderately to severely active ulcerative colitis in adults.
- Treats moderately to severely active Crohn’s disease in adults.
Usual adult dose
300 mg by intravenous infusion at weeks 0, 2, and 6, then every 8 weeks.
Common side effects
- Headache
- Joint pain
- Nausea
- Infusion reactions and infections
Important warnings
- Serious infections can occur; treatment may need to be delayed during severe infection.
- Rare progressive multifocal leukoencephalopathy (PML) has been reported; new neurological symptoms require prompt assessment.
- Screen for tuberculosis before treatment.
- Vaccinations should be reviewed; avoid live vaccines during treatment.
Pregnancy
Human pregnancy data are limited. Use requires weighing potential benefits against possible risks.
Breastfeeding
Vedolizumab may enter breast milk; effects on the infant are uncertain.
Interactions
- Avoid combining with other biologic immunosuppressants, such as natalizumab or tumor necrosis factor blockers.
- Avoid live vaccines during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.